Catalyst Dossier · compiled by CeliA 🧫
Allergy Therapeutics plc (AGY.L)
Pharmaceutical Preparations · market cap $6M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-15 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
4
next 90d+
Dossier
Not yet
generate it
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
The catalyst path
- 2026-12-15 (est.)Phase 2 · 6-diazo-5-oxo-L-norleucine (DON)imp 7/10
- 2027-04-05 (est.)Phase 2 · MTBVACimp 7/10
- 2027-05-01 (est.)Phase 2 · Research Grade RG-RVimp 7/10
- 2027-05-05 (est.)Phase 3 · Dihydroartemisinin-piperaquine (DP)imp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Vaxchora | Phase 2 | Cholera |
| Peanut Flour | Phase 2 | Peanut Allergy |
| SUBLIVAC FIX Birch | Phase 2 | Allergic Rhinitis |
| SUBLIVAC® Grasses treatment | Phase 3 | Rhinitis, Allergic, Seasonal |
| sublingual immunotherapy | Phase 2 | Seasonal Rhinitis and/or Rhinoconjunctivitis |
| cotrimoxazole prophylaxis | Phase 2 | HIV Infections |
| PURETHAL Mites 50,000 AUeq/ml | Phase 3 | House Dust Mite Allergy |
| SUBLIVAC FIX phleum prat. | Phase 2 | Allergic Rhinitis |
| Rilpivirine | Phase 2 | Human Immunodeficiency Virus (HIV) |
| PURETHAL Mites 20,000 AUeq/ml | Phase 2 | Allergic Rhinitis |
| Grass MATAMPL | Phase 2 | Type I Hypersensitivity |
| Tree MATA MPL | Phase 2 | Type I Hypersensitivity |
| PURETHAL Mites 6,667 AU/ml | Phase 2 | Allergic Rhinitis |
| Grass MATA MPL (0.5ml) 5100SU | Phase 2 | Seasonal Allergic Rhinitis |
| TreeMATA MPL | Phase 2 | Type I Hypersensitivity |
| Ragweed MATA MPL | Phase 3 | Type I Hypersensitivity |
| PQ Grass | Phase 3 | Rhinitis, Allergic, Seasonal |
| SUBLIVAC FIX Mite mixture | Phase 2 | House Dust Mite Allergy |
| Ragweed MATAMPL | Phase 2 | Type I Hypersensitivity |
| Tree MATA MPL - Therapeutic Regimen | Phase 2 | Type I Hypersensitivity |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AGY.L (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.